17-61379228-C-T
Variant names:
Variant summary
Our verdict is Benign. The variant received -10 ACMG points: 0P and 10B. BP4_ModerateBA1
The NM_017679.5(BCAS3):c.2593+10734C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.691 in 152,070 control chromosomes in the GnomAD database, including 37,941 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.69 ( 37924 hom., cov: 32)
Exomes 𝑓: 0.83 ( 17 hom. )
Consequence
BCAS3
NM_017679.5 intron
NM_017679.5 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.263
Publications
78 publications found
Genes affected
BCAS3 (HGNC:14347): (BCAS3 microtubule associated cell migration factor) Enables several functions, including acetyltransferase activator activity; beta-tubulin binding activity; and histone acetyltransferase binding activity. Involved in cellular response to estrogen stimulus; positive regulation of catalytic activity; and positive regulation of transcription by RNA polymerase II. Located in nucleus; phagophore assembly site; and transcriptionally active chromatin. Biomarker of breast cancer. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -10 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.42).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.811 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.691 AC: 105036AN: 151898Hom.: 37910 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
105036
AN:
151898
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.827 AC: 43AN: 52Hom.: 17 Cov.: 0 AF XY: 0.857 AC XY: 24AN XY: 28 show subpopulations
GnomAD4 exome
AF:
AC:
43
AN:
52
Hom.:
Cov.:
0
AF XY:
AC XY:
24
AN XY:
28
show subpopulations
African (AFR)
AF:
AC:
1
AN:
2
American (AMR)
AF:
AC:
1
AN:
2
Ashkenazi Jewish (ASJ)
AC:
0
AN:
0
East Asian (EAS)
AC:
0
AN:
0
South Asian (SAS)
AC:
0
AN:
0
European-Finnish (FIN)
AF:
AC:
10
AN:
10
Middle Eastern (MID)
AF:
AC:
2
AN:
2
European-Non Finnish (NFE)
AF:
AC:
25
AN:
30
Other (OTH)
AF:
AC:
4
AN:
6
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.558
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.691 AC: 105096AN: 152018Hom.: 37924 Cov.: 32 AF XY: 0.684 AC XY: 50835AN XY: 74312 show subpopulations
GnomAD4 genome
AF:
AC:
105096
AN:
152018
Hom.:
Cov.:
32
AF XY:
AC XY:
50835
AN XY:
74312
show subpopulations
African (AFR)
AF:
AC:
21815
AN:
41420
American (AMR)
AF:
AC:
8703
AN:
15272
Ashkenazi Jewish (ASJ)
AF:
AC:
2625
AN:
3470
East Asian (EAS)
AF:
AC:
2497
AN:
5160
South Asian (SAS)
AF:
AC:
2923
AN:
4816
European-Finnish (FIN)
AF:
AC:
8508
AN:
10588
Middle Eastern (MID)
AF:
AC:
207
AN:
294
European-Non Finnish (NFE)
AF:
AC:
55549
AN:
67978
Other (OTH)
AF:
AC:
1441
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1535
3070
4604
6139
7674
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1918
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.